Discontinuation of Oral Anticoagulation After Successful Atrial Fibrillation Ablation – Are We Ready to Change Clinical Practice in 2026?

08 May 2026 : Review article

Karol Momot

^{ABCDEFG 1,2}, Stanisław Surma

^{ABEF 3}, Kamil Krauz

^{DEF 1,4*}, Michał Pruc

^{BEF 5}, Łukasz Szarpak

^{DEF 5,6}, Dariusz Rodkiewicz

^{EF 2}, Małgorzata Buksińska-Lisik

^{EF 2}, Artur Mamcarz

^{AE 2}

DOI: 10.12659/MSM.952757

Med Sci Monit 2026; 32:e952757

Authors information Article notes Copyright and License information

Introduction Evidence Prior to Randomized Controlled Trials Data From Prospective Randomized Controlled Trials Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 3 Comparison of selected endpoint outcomes between study groups.

	OCEAN		ALONE-AF
	Interventionn=643Aspirin	Controln=641Rivaroxaban	Interventionn=417Discontinued	Controln=423Continued
All Stroke, n (%)	7 (1.1%)	5 (0.8%)	1 (0.3%)	5 (1.4%)
Embolic stroke, n (%)	2 (0.3%)	0 (0.0%)	1 (0.3%)	3 (0.8%)
Systemic embolism, n (%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Transient ischemic attack, n (%)	5 (0.8%)	1 (0.2%)	2 (0.6%)	0 (0.0%)
Major bleeding, n (%)	4 (0.6%)	10 (1.6%)	0 (0.0%)	5 (1.4%)
Clinically relevant nonmajor bleeding, n (%)	10 (1.6%)	35 (5.5%)	5 (1.4%)	7 (1.9%)
Death from any cause, n (%)	7 (1.1%)	10 (1.6%)	0 (0.0%)	0 (0.0%)

Back to the Article